Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects

Trial Profile

Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Diacerein (Primary)
  • Indications Fatty liver; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DGCLFT2DM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
    • 05 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top